{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:42:04Z","timestamp":1788903724671,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MAPS Public Benefit Corp"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Rationale<\/jats:title>\n                <jats:p>MDMA-assisted psychotherapy is under investigation as a novel treatment for posttraumatic stress disorder (PTSD). The primary mechanism of action of MDMA involves the same reuptake transporters targeted by antidepressant medications commonly prescribed for PTSD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Data were pooled from four phase 2 trials of MDMA-assisted psychotherapy. To explore the effect of tapering antidepressant medications, participants who had been randomized to receive active doses of MDMA (75\u2013125\u00a0mg) were divided into two groups (taper group (<jats:italic>n<\/jats:italic>\u2009=\u200916) or non-taper group (<jats:italic>n<\/jats:italic>\u2009=\u200934)).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between-group comparisons were made for PTSD and depression symptom severity at the baseline and the primary endpoint, and for peak vital signs across two MDMA sessions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Demographics, baseline PTSD, and depression severity were similar between the taper and non-taper groups. At the primary endpoint, the non-taper group (mean\u2009=\u200945.7, SD\u2009=\u200927.17) had a significantly (<jats:italic>p<\/jats:italic>\u2009=\u20090.009) lower CAPS-IV total scores compared to the taper group (mean\u2009=\u200970.3, SD\u2009=\u200933.60). More participants in the non-taper group (63.6%) no longer met PTSD criteria at the primary endpoint than those in the taper group (25.0%). The non-taper group (mean\u2009=\u200912.7, SD\u2009=\u200910.17) had lower depression symptom severity scores (<jats:italic>p<\/jats:italic>\u2009=\u20090.010) compared to the taper group (mean\u2009=\u200922.6, SD\u2009=\u200916.69). There were significant differences between groups in peak systolic blood pressure (<jats:italic>p<\/jats:italic>\u2009=\u20090.043) and diastolic blood pressure (<jats:italic>p<\/jats:italic>\u2009=\u20090.032).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Recent exposure to antidepressant drugs that target reuptake transporters may reduce treatment response to MDMA-assisted psychotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00213-020-05710-w","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T20:02:47Z","timestamp":1605988967000},"page":"581-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["RETRACTED ARTICLE: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy"],"prefix":"10.1007","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6918-0738","authenticated-orcid":false,"given":"Allison A.","family":"Feduccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Jerome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Mithoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,21]]},"reference":[{"key":"5710_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuroimage.2013.10.002","volume":"88","author":"P Baldinger","year":"2014","unstructured":"Baldinger P, Kranz GS, Haeusler D, Savli M, Spies M, Philippe C, Hahn A, Hoflich A, Wadsak W, Mitterhauser M, Lanzenberger R, Kasper S (2014) Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. NeuroImage 88:252\u2013262","journal-title":"NeuroImage"},{"key":"5710_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","volume":"67","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Ball R, Ranieri W (1996) Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 67:588\u2013597","journal-title":"J Pers Assess"},{"key":"5710_CR3","doi-asserted-by":"publisher","first-page":"10494","DOI":"10.1523\/JNEUROSCI.19-23-10494.1999","volume":"19","author":"S Benmansour","year":"1999","unstructured":"Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A (1999) Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19:10494\u201310501","journal-title":"J Neurosci"},{"key":"5710_CR4","first-page":"75","volume":"8","author":"DD Blake","year":"1995","unstructured":"Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM (1995) The development of a clinician-administered PTSD scale. J Trauma Stress 8:75\u201390","journal-title":"J Trauma Stress"},{"key":"5710_CR5","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"AL Danforth","year":"2018","unstructured":"Danforth AL, Grob CS, Struble C, Feduccia AA, Walker N, Jerome L, Yazar-Klosinski B, Emerson A (2018) Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology 235:3137\u20133148","journal-title":"Psychopharmacology"},{"key":"5710_CR6","unstructured":"Davies J, Pauli R, Montagu L (2018) Antidepressant withdrawal: a survey of patients\u2019 experience by the All-Party Parliamentary Group for Prescribed Drug Dependence. APPG for PDD\u2013All-Party Parliamentary Group for Prescribed Drug Dependence. http:\/\/www.prescribeddrugorg\/wp-content\/uploads\/2018\/09\/APPG-PDD-Antidepressant-Withdrawal-Patient-Survey.pdf"},{"key":"5710_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/17470910802649470","volume":"4","author":"GJ Dumont","year":"2009","unstructured":"Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, van Gerven JM, Buitelaar JK, Verkes RJ (2009) Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci 4:359\u2013366","journal-title":"Soc Neurosci"},{"key":"5710_CR8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.107.129056","volume":"323","author":"M Farre","year":"2007","unstructured":"Farre M, Abanades S, Roset PN, Peiro AM, Torrens M, O'Mathuna B, Segura M, de la Torre R (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323:954\u2013962","journal-title":"J Pharmacol Exp Ther"},{"key":"5710_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0166-4328(96)00078-2","volume":"73","author":"CS Grob","year":"1996","unstructured":"Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73:103\u2013107","journal-title":"Behav Brain Res"},{"key":"5710_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/mp.2013.147","volume":"19","author":"ME Haahr","year":"2014","unstructured":"Haahr ME, Fisher PM, Jensen CG, Frokjaer VG, Mahon BM, Madsen K, Baare WF, Lehel S, Norremolle A, Rabiner EA, Knudsen GM (2014) Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study. Mol Psychiatry 19:427\u2013432","journal-title":"Mol Psychiatry"},{"key":"5710_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/157015911795017254","volume":"9","author":"Y Hagino","year":"2011","unstructured":"Hagino Y, Takamatsu Y, Yamamoto H, Iwamura T, Murphy DL, Uhl GR, Sora I, Ikeda K (2011) Effects of MDMA on extracellular dopamine and serotonin levels in mice lacking dopamine and\/or serotonin transporters. Curr Neuropharmacol 9:91\u201395","journal-title":"Curr Neuropharmacol"},{"key":"5710_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa040603","volume":"351","author":"CW Hoge","year":"2004","unstructured":"Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL (2004) Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 351:13\u201322","journal-title":"N Engl J Med"},{"key":"5710_CR13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","volume":"6","author":"MA Horowitz","year":"2019","unstructured":"Horowitz MA, Taylor D (2019) Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 6:538\u2013546","journal-title":"Lancet Psychiatry"},{"key":"5710_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00213-012-2761-6","volume":"224","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Liechti ME (2012) Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology 224:363\u2013376","journal-title":"Psychopharmacology"},{"key":"5710_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00213-012-2645-9","volume":"222","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Domes G, Liechti ME (2012) MDMA enhances \u201cmind reading\u201d of positive emotions and impairs \u201cmind reading\u201d of negative emotions. Psychopharmacology 222:293\u2013302","journal-title":"Psychopharmacology"},{"key":"5710_CR16","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/scan\/nst161","volume":"9","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, Preller KH, Quednow BB, Liechti ME (2014) MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci 9:1645\u20131652","journal-title":"Soc Cogn Affect Neurosci"},{"key":"5710_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/0269881115573806","volume":"29","author":"M Kirkpatrick","year":"2015","unstructured":"Kirkpatrick M, Delton AW, Robertson TE, de Wit H (2015) Prosocial effects of MDMA: a measure of generosity. J Psychopharmacol 29:661\u2013668","journal-title":"J Psychopharmacol"},{"key":"5710_CR18","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1017\/S0033291717000708","volume":"47","author":"KC Koenen","year":"2017","unstructured":"Koenen KC, Ratanatharathorn A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, Karam EG, Meron Ruscio A, Benjet C, Scott K, Atwoli L, Petukhova M, Lim CCW, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Bunting B, Ciutan M, de Girolamo G, Degenhardt L, Gureje O, Haro JM, Huang Y, Kawakami N, Lee S, Navarro-Mateu F, Pennell BE, Piazza M, Sampson N, Ten Have M, Torres Y, Viana MC, Williams D, Xavier M, Kessler RC (2017) Posttraumatic stress disorder in the world mental health surveys. Psychol Med 47:2260\u20132274","journal-title":"Psychol Med"},{"key":"5710_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4161\/23328940.2014.955433","volume":"1","author":"ME Liechti","year":"2014","unstructured":"Liechti ME (2014) Effects of MDMA on body temperature in humans. Temperature 1:192\u2013200","journal-title":"Temperature"},{"key":"5710_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hup.348","volume":"16","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Vollenweider FX (2001) Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 16:589\u2013598","journal-title":"Hum Psychopharmacol"},{"key":"5710_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","volume":"22","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513\u2013521","journal-title":"Neuropsychopharmacology"},{"key":"5710_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1381612053382223","volume":"11","author":"JE Malberg","year":"2005","unstructured":"Malberg JE, Schechter LE (2005) Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 11:145\u2013155","journal-title":"Curr Pharm Des"},{"key":"5710_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1176\/appi.ajp.158.1.78","volume":"158","author":"JH Meyer","year":"2001","unstructured":"Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH (2001) The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 158:78\u201385","journal-title":"Am J Psychiatry"},{"key":"5710_CR24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","volume":"161","author":"JH Meyer","year":"2004","unstructured":"Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826\u2013835","journal-title":"Am J Psychiatry"},{"key":"5710_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of {+\/\u2212}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439\u2013452","journal-title":"J Psychopharmacol"},{"key":"5710_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","volume":"5","author":"MC Mithoefer","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R (2018) 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5:486\u2013497","journal-title":"Lancet Psychiatry"},{"key":"5710_CR27","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"MC Mithoefer","year":"2019","unstructured":"Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R (2019) MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 236:2735\u20132745","journal-title":"Psychopharmacology"},{"key":"5710_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00004714-199304000-00004","volume":"13","author":"LM Nagy","year":"1993","unstructured":"Nagy LM, Morgan CA 3rd, Southwick SM, Charney DS (1993) Open prospective trial of fluoxetine for posttraumatic stress disorder. J Clin Psychopharmacol 13:107\u2013113","journal-title":"J Clin Psychopharmacol"},{"key":"5710_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U (2013) A randomized, controlled pilot study of MDMA (+\/\u2212 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol 27:40\u201352","journal-title":"J Psychopharmacol"},{"key":"5710_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/00023210-199912030-00001","volume":"12","author":"JS Olver","year":"1999","unstructured":"Olver JS, Burrows GD, Norman TR (1999) Discontinuation syndromes with selective serotonin reuptake inhibitors. CNS drugs 12:171\u2013177","journal-title":"CNS drugs"},{"key":"5710_CR31","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"GM Ot\u2019alora","year":"2018","unstructured":"Ot\u2019alora GM, Grigsby J, Poulter B, Van Derveer JW 3rd, Giron SG, Jerome L, Feduccia AA, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R (2018) 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J Psychopharmacol 32:1295\u20131307","journal-title":"J Psychopharmacol"},{"key":"5710_CR32","first-page":"561","volume":"288","author":"DK Raap","year":"1999","unstructured":"Raap DK, Garcia F, Muma NA, Wolf WA, Battaglia G, van de Kar LD (1999) Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi\/o\/z proteins. J Pharmacol Exp Ther 288:561\u2013567","journal-title":"J Pharmacol Exp Ther"},{"key":"5710_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4065\/76.5.511","volume":"76","author":"E Richelson","year":"2001","unstructured":"Richelson E (2001) Pharmacology of antidepressants. Mayo Clin Proc 76:511\u2013527","journal-title":"Mayo Clin Proc"},{"key":"5710_CR34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/PSY.0b013e31803146d8","volume":"69","author":"J Sareen","year":"2007","unstructured":"Sareen J, Cox BJ, Stein MB, Afifi TO, Fleet C, Asmundson GJ (2007) Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample. Psychosom Med 69:242\u2013248","journal-title":"Psychosom Med"},{"key":"5710_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/jts.20497","volume":"23","author":"MT Shea","year":"2010","unstructured":"Shea MT, Vujanovic AA, Mansfield AK, Sevin E, Liu F (2010) Posttraumatic stress disorder symptoms and functional impairment among OEF and OIF National Guard and reserve veterans. J Trauma Stress 23:100\u2013107","journal-title":"J Trauma Stress"},{"key":"5710_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","volume":"51","author":"SM Stahl","year":"1998","unstructured":"Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51:215\u2013235","journal-title":"J Affect Disord"},{"key":"5710_CR37","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuropharm.2012.10.002","volume":"67","author":"FR Walker","year":"2013","unstructured":"Walker FR (2013) A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology 67:304\u2013317","journal-title":"Neuropharmacology"},{"issue":"Suppl","key":"5710_CR38","first-page":"19","volume":"48","author":"JK Wamsley","year":"1987","unstructured":"Wamsley JK, Byerley WF, McCabe RT, McConnell EJ, Dawson TM, Grosser BI (1987) Receptor alterations associated with serotonergic agents: an autoradiographic analysis. The Journal of clinical psychiatry 48(Suppl):19\u201325","journal-title":"The Journal of clinical psychiatry"},{"key":"5710_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/da.1029","volume":"13","author":"FW Weathers","year":"2001","unstructured":"Weathers FW, Keane TM, Davidson JR (2001) Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety 13:132\u2013156","journal-title":"Depress Anxiety"}],"updated-by":[{"DOI":"10.1007\/s00213-024-06671-0","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"record-id":"55620"},{"DOI":"10.1007\/s00213-024-06671-0","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000}}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05710-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-020-05710-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05710-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T07:04:51Z","timestamp":1723273491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-020-05710-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,21]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5710"],"URL":"https:\/\/doi.org\/10.1007\/s00213-020-05710-w","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,21]]},"assertion":[{"value":"27 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00213-024-06671-0","URL":"https:\/\/doi.org\/10.1007\/s00213-024-06671-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}